Stay updated on Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial page.

Latest updates to the Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check24 days agoChange DetectedDifference0.3%
- Check32 days agoChange DetectedThe web page has undergone significant content removal, including the detailed description of a Phase 1/2 study evaluating Loncastuximab Tesirine and Ibrutinib for lymphoma treatment, which is critical information for potential participants and stakeholders. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference25%
- Check39 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check46 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check53 days agoChange DetectedDifference0.1%
Stay in the know with updates to Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial page.